Monday, October 5, 2026

83% of Organizations Struggle with AI Infrastructure as Cloud Adoption Accelerates

83% of organizations report their internal teams are struggling with AI workloads, driving rapid adoption of cloud-based infrastructure. 97% of companies now consider cloud essential for scaling AI, with 72% relying on third-party expertise to manage growing complexity.

83% of Organizations Struggle with AI Infrastructure as Cloud Adoption Accelerates
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

83% of organizations say their internal teams are struggling with AI workloads, according to recent industry data tracking enterprise AI adoption patterns. The statistic highlights a widening gap between AI ambitions and operational capacity.

97% of organizations agree cloud infrastructure is essential to scaling AI initiatives. More than half cite cloud as their fastest path to production, bypassing lengthy on-premises deployments.

65% of organizations now describe their AI environments as too complex to manage internally. This complexity is driving outsourcing: 72% rely on third-party expertise to build and manage AI infrastructure.

Cloud providers are responding with specialized offerings. Akamai recently launched its Inference Cloud service, joining AWS, Google Cloud, and Microsoft Azure in the race for AI infrastructure market share. These platforms handle model deployment, scaling, and optimization tasks that internal teams find overwhelming.

The shift reflects economic pressure. Companies face costs for GPU clusters, storage systems, networking infrastructure, and specialized talent. Cloud-based AI services convert these capital expenses into operational costs with predictable monthly billing.

AI infrastructure-as-a-service platforms now handle workloads ranging from natural language processing to computer vision. Managed services include model hosting, automatic scaling, monitoring, and compliance frameworks that organizations lack internally.

The complexity issue stems from multiple factors: rapid evolution of AI frameworks, diverse hardware requirements across workloads, integration with existing data systems, and shortage of engineers with AI infrastructure expertise. Organizations report spending months on infrastructure setup before running their first production model.

Third-party providers offer immediate access to pre-configured environments. They maintain expertise across multiple AI frameworks and handle updates as tools evolve. For many companies, this expertise gap makes cloud adoption inevitable rather than optional.

Strong current adoption data supports cloud AI growth projections. Quarterly revenue reports from major cloud providers will test whether this infrastructure shift continues accelerating through 2027.

In this story

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com